DOCSLIB.ORG

Irritable Bowel Syndrome and Probiotics: from Rationale to Clinical Use Elena F

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Irritable Bowel Syndrome and Probiotics: from Rationale to Clinical Use Elena F Irritable bowel syndrome and probiotics: from rationale to clinical use Elena F. Verdu and Stephen M. Collins Purpose of review Introduction Few therapies are of proven efficacy in irritable bowel In this review we discuss the gut-driven pathophysiologic syndrome. Thus, there is great interest in the development pathways involved in gut dysfunction and symptom gen- of a natural therapy that can be both safe and effective. An eration in irritable bowel syndrome (IBS), including immune understanding that probiotics are heterogeneous, with activation, dysmotility, altered mucosal barrier function, multiple targets and mechanisms of action, is fundamental and visceral perception. This allows us to logically review to the development of clinical trials. the possible targets of probiotic therapy in IBS. Finally, we Recent findings evaluate the relevant clinical trials published to date on A bidirectional model for the pathogenesis of irritable bowel probiotics and IBS. syndrome is proposed in which gut-driven and brain-driven mechanisms contribute to the genesis of gut dysfunction and symptoms. In-vitro and animal studies have generated Gut dysfunction in irritable bowel syndrome most of the mechanistic rationale for the use of probiotics The current goal of treatment in IBS is to alleviate symp- in functional bowel disorders. A MEDLINE search of toms and improve quality of life. The gut-driven patho- publications from 1989 to date revealed only eight physiologic mechanisms believed to be involved in the placebo-controlled clinical trials on the subject of origin or maintenance of IBS symptoms include intestinal probiotics and irritable bowel syndrome. All these studies infection and immune activation, dysmotility, abnormal • suffer from methodologic problems. By contrast, fermentation, and visceral hypersensitivity [1–4,5 ,6–10]. numerous reviews have been published in the past 2 years Therapeutic approaches targeting some of these mecha- on this subject. nisms have been developed and used with varied clinical Summary efficacy [11]. Animal research will continue to identify novel targets and elucidate the mechanisms of action of probiotics, thus Increased intestinal permeability and abnormal central providing a rational basis for their use in irritable bowel processing of peripheral stimuli have also been proposed syndrome. The notion of treating irritable bowel syndrome as possible mechanisms leading to or exacerbating IBS with probiotics is particularly attractive to patients and symptoms [12]. Changes in gut permeability have been generates great interest, although clinical evidence is not demonstrated in postinfective IBS (PI-IBS), but this has yet sufficient to enable clear guidelines to be designed. not been proved in the unselected IBS population [2]. Large, well-designed, controlled clinical trials using specific probiotics are warranted. It is the opinion of the authors that low-grade inflamma- tion is the basis for gut dysfunction in a proportion of Keywords patients with IBS. A recent study has shown that Bifido- functional bowel disorders, gut dysfunction, irritable bowel bacterium infantis 35634 improved systemic cytokine abnor- •• syndrome, probiotics malities and normalized symptoms in IBS patients [13 ]. This raises the possibility that specific probiotics may Curr Opin Gastroenterol 21:697——701. ª 2005 Lippincott Williams & Wilkins. modify the natural history of IBS. Intestinal Disease Research Programme, McMaster University, Hamilton, Ontario, Canada Immune activation in irritable bowel syndrome Correspondence to Elena F Verdu, 1200 Main Street West, McMaster University, Hamilton, Ontario, Canada Infectious gastroenteritis is the most significant environ- Tel: 905 525 9140 x22212; fax: 905 521 3454; e-mail: [email protected] mental risk factor identified to date for the development Current Opinion in Gastroenterology 2005, 21:697——701 of IBS [1]. IBS symptoms have been reported to develop Abbreviations in a significant proportion of individuals with documented Campylobacter, Salmonella, Escherichia coli, and Shigella infec- IBS irritable bowel syndrome PI-IBS postinfective irritable bowel syndrome tion as well as viral infection [2,14–16]. Evidence of immune activation is not restricted to patients with ª 2005 Lippincott Williams & Wilkins. PI-IBS, and it has also been reported in a proportion of 0267-1379 unselected IBS patients with no history of gastroenteritis [2–4,5•,17]. 697 698 Immunology There is evidence for an imbalance in the genetic regula- in children with atopic dermatitis [27]. Other studies, tion of counterinflammatory cytokine secretion in patients however, using a variety of probiotic species in critically with IBS [18]. This may promote a defective downregu- ill patients, failed to demonstrate improvement in intes- lation of immune responses to normal inflammatory stim- tinal permeability despite favorable changes in the uli in IBS. A recent study by Van Der Veek et al. [19] systemic inflammatory response and the microbial compo- demonstrated changes in the genetic control of cytokines sition of the gastrointestinal tract [28,29]. The identifi- that play a critical role in regulating inflammation in the cation of subgroups of IBS patients in whom barrier gut. The combination of genotypes encoding for high dysfunction underlies symptom generation should be a tumor necrosis factor-a secretion, a proinflammatory cyto- prior logical step to the application of probiotic therapy kine, and low interleukin-10 secretion, a counterregula- to target barrier dysfunction. tory cytokine, was significantly more prevalent in IBS patients than in control individuals. Phenotypic evidence Dysmotility is considered to underlie altered bowel habit, demonstrating a lower ration of interleukin-10 to tumor whichisacommonsymptominIBSpatients.Until necrosis factor-a in IBS patients has recently confirmed recently, the neuromuscular apparatus was not considered these earlier genotypic studies [13••]. as a possible target for probiotic therapy, presumably because of its distance from the lumen. Of five different Putative mechanisms of action of probiotics probiotic species tested, only L. paracasei was able to sig- in irritable bowel syndrome nificantly attenuate muscle dysfunction in the model of Inflammatory bowel syndrome is heterogeneous both in Trichinella spiralis-induced IBS. The beneficial effect was its clinical presentation and in its pathogenesis. No treat- observed even when the probiotic was administered long ment to date has been proved to be substantially effective, after resolution of the initial infection [25]. L. paracasei although a recent study by O’Mahony et al. [13••]is significantly improved postinfective dysmotility in vivo, encouraging. Probiotics may target one or more patho- as assessed by video fluoroscopy and image analysis. Oral physiologic pathways in IBS, and specific probiotics with administration of spent culture medium from L. paracasei, more than one mechanism of action may prove to be an devoid of live bacteria, also improved postinfective dysmo- attractive ‘natural’ approach compared with conventional tility [30]. Taken together, these studies demonstrate that drug therapy for patients with IBS. Eventually, combina- specific probiotics may target the neuromuscular appara- tions of specific strains carefully selected on the basis of tus and improve muscle function in PI-IBS. documented targets in the gastrointestinal tract may pro- vide the best therapeutic approach. Bloating and abdominal distension is commonly present in patients with IBS. Dysmotility and consequently diffi- A recent metaanalysis has shown that probiotic therapy culty in propelling gas may underlie these symptoms. King reduces the duration of infectious diarrhea in children et al. [31] have shown a greater gas production in IBS [20]. This is particularly relevant to PI-IBS, in which a patients than in control individuals, which suggests that shorter duration of the initial gastroenteritis episode or abnormal fermentation may be responsible for bloating prevention of colonization by pathogens may reduce the in some IBS patients. Probiotics aimed at reducing abnor- risk for the subsequent development of IBS [21,22]. mal fermentation may be useful only in those patients in whom abnormal fermentation due to altered flora can be Numerous studies have demonstrated antiinflammatory documented [32]. effects of probiotics in animal models of inflammatory bowel disease [23,24]. We have shown in a murine model Pain is a cardinal symptom in IBS, and visceral hypersen- of PI-IBS that Lactobacillus paracasei NCC2461 attenuates sitivity is believed to underlie this symptom. There is postinfective muscle contractility, in part through modu- some evidence that specific probiotics may modulate neu- lation of the inflammatory response to infection [25•]. rotransmission in the gut. The administration of Saccaro- Recently, L. salivarius UCC4331 and B. infantis 35624 myces boulardii to pigs has been shown to modulate the have been shown to reduce an abnormal systemic ratio of expression of neuronal markers in the submucous plexus interleukin-10 to interleukin-12 in patients with IBS [13••]. [33]. L. farciminis has been shown to attenuate visceral hypersensitivity in rats [26]. We have found that the Lactobacillus farciminis was shown to enhance barrier func- administration of L. paracasei NCC2461 attenuates the vis- tion and prevent bacterial translocation in trinitrobenzene ceral hypersensitivity and sensory neurotransmitter expres-
Load more

Recommended publications
  • The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio In
    microorganisms Review The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease Spase Stojanov 1,2, Aleš Berlec 1,2 and Borut Štrukelj 1,2,* 1 Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia; [email protected] (S.S.); [email protected] (A.B.) 2 Department of Biotechnology, Jožef Stefan Institute, SI-1000 Ljubljana, Slovenia * Correspondence: borut.strukelj@ffa.uni-lj.si Received: 16 September 2020; Accepted: 31 October 2020; Published: 1 November 2020 Abstract: The two most important bacterial phyla in the gastrointestinal tract, Firmicutes and Bacteroidetes, have gained much attention in recent years. The Firmicutes/Bacteroidetes (F/B) ratio is widely accepted to have an important influence in maintaining normal intestinal homeostasis. Increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed with obesity, and the latter with inflammatory bowel disease (IBD). Probiotics as live microorganisms can confer health benefits to the host when administered in adequate amounts. There is considerable evidence of their nutritional and immunosuppressive properties including reports that elucidate the association of probiotics with the F/B ratio, obesity, and IBD. Orally administered probiotics can contribute to the restoration of dysbiotic microbiota and to the prevention of obesity or IBD. However, as the effects of different probiotics on the F/B ratio differ, selecting the appropriate species or mixture is crucial. The most commonly tested probiotics for modifying the F/B ratio and treating obesity and IBD are from the genus Lactobacillus. In this paper, we review the effects of probiotics on the F/B ratio that lead to weight loss or immunosuppression.
    [Show full text]
  • Administration of L. Salivarius Expressing 3D8 Scfv As a Feed Additive Improved the Growth Performance, Immune Homeostasis, and Gut Microbiota of Chickens
    Received: 22 January 2020 | Revised: 2 April 2020 | Accepted: 24 April 2020 DOI: 10.1111/asj.13399 ORIGINAL ARTICLE Administration of L. salivarius expressing 3D8 scFv as a feed additive improved the growth performance, immune homeostasis, and gut microbiota of chickens Shanmugam Sureshkumar1,2 | Sun Keun Jung1 | Dongjun Kim3 | Keon Bong Oh1 | Hyeon Yang1 | Hwi Cheul Lee1 | Yong Jin Jo1 | Hae Sun Lee1 | Sukchan Lee3 | Sung June Byun1 1Animal Biotechnology Division, National Institute of Animal Science, Rural Abstract Development Administration, Wanju-gun, Probiotics have been defined as live microorganisms that are administered in an ap- Republic of Korea propriate amount to provide health benefits to the host animal. In this study, we in- 2Department of Animal Resource and Science, Dankook University, Cheonan, vestigated the effect of L. salivarius DJ-sa-01 secreting the 3D8 single-chain variable Republic of Korea fragment (3D8 scFv) on the growth performance, cytokine secretion, and intestinal 3Department of Integrative Biotechnology, Sungkyunkwan University, Gyeonggi-do, microbial flora of chickens. The experiment was divided into the control group and Republic of Korea L. salivarius expressing 3D8 scFv experimental group. Chicken was fed 109 colony- Correspondence forming units (CFUs) of wild-type (WT) L. salivarius or 3D8 scFv-secreting L. salivarius Sung June Byun, Animal Biotechnology daily for 35 days. The administration of L. salivarius expressing 3D8 scFv signifi- Division, National Institute of Animal Science, Rural Development Administration, cantly improved the body weight of chickens compared with the administration of 1500, Wanju-gun, 441-706, Republic of WT L. salivarius. A 16S ribosomal RNA metagenomic analysis showed that Firmicutes, Korea.
    [Show full text]
  • Guide to Probiotics
    Department of Nutrition and Dietetics 01935 384250 Guide to Probiotics If you would like this leaflet in another format or in a different language, please contact the hospital’s communications Department of Nutrition department on 01935 384233 or email and Dietetics— 01935 384250 [email protected] Leaflet No: 88061014 Date: 12/14 Review by: 12/16 www.yeovilhospital.nhs.uk Bio-Kult Bacillus subtilis Minimum 2 Tablet Online Bifidobacterium bifidum billion live www.bio-kult.com Bifidobacterium breve microorganisms Bifidobacterium infantis per capsule Also available in some Bifidobacterium longum shops. Lactobacillus acidophilus L.delbrueckii ssp. Bulgaricus L. casei L. plantarum L. rhamnosus L. Helveticus L. Salivarius Lactococcus lactis ssp. Lactis Streptococcus thermophiles Biogaia Lactobacillus reu- Minimum 200 Lozenge Online teri Protectis million live www.biogaia.co.uk bacteria in 1 lozenge Recommended use: Please note that some patients experience a slight increase in their symptoms in the first week of us- ing a high dose probiotic. Just bear with it but if you are concerned, please contact us. Introduction The human gut contains millions of bacteria living in balance with each other. This balance can be upset for various reasons including antibiotic use or following an upset stomach when certain bacteria grow in higher numbers than usual. What are probiotics? Available Available from Hollandand Barrett Online www.symprove.com Or via telephone 01252 413600 Available from Probiotics are live bacteria often referred to as ‘good’ or ‘friendly’ bacteria, which may have health benefits by improving the balance of our gut bacteria. They may help if suffering with wind, bloating or constipation or if affected by antibiotic associated bacteria.
    [Show full text]
  • A Taxonomic Note on the Genus Lactobacillus
    Taxonomic Description template 1 A taxonomic note on the genus Lactobacillus: 2 Description of 23 novel genera, emended description 3 of the genus Lactobacillus Beijerinck 1901, and union 4 of Lactobacillaceae and Leuconostocaceae 5 Jinshui Zheng1, $, Stijn Wittouck2, $, Elisa Salvetti3, $, Charles M.A.P. Franz4, Hugh M.B. Harris5, Paola 6 Mattarelli6, Paul W. O’Toole5, Bruno Pot7, Peter Vandamme8, Jens Walter9, 10, Koichi Watanabe11, 12, 7 Sander Wuyts2, Giovanna E. Felis3, #*, Michael G. Gänzle9, 13#*, Sarah Lebeer2 # 8 '© [Jinshui Zheng, Stijn Wittouck, Elisa Salvetti, Charles M.A.P. Franz, Hugh M.B. Harris, Paola 9 Mattarelli, Paul W. O’Toole, Bruno Pot, Peter Vandamme, Jens Walter, Koichi Watanabe, Sander 10 Wuyts, Giovanna E. Felis, Michael G. Gänzle, Sarah Lebeer]. 11 The definitive peer reviewed, edited version of this article is published in International Journal of 12 Systematic and Evolutionary Microbiology, https://doi.org/10.1099/ijsem.0.004107 13 1Huazhong Agricultural University, State Key Laboratory of Agricultural Microbiology, Hubei Key 14 Laboratory of Agricultural Bioinformatics, Wuhan, Hubei, P.R. China. 15 2Research Group Environmental Ecology and Applied Microbiology, Department of Bioscience 16 Engineering, University of Antwerp, Antwerp, Belgium 17 3 Dept. of Biotechnology, University of Verona, Verona, Italy 18 4 Max Rubner‐Institut, Department of Microbiology and Biotechnology, Kiel, Germany 19 5 School of Microbiology & APC Microbiome Ireland, University College Cork, Co. Cork, Ireland 20 6 University of Bologna, Dept. of Agricultural and Food Sciences, Bologna, Italy 21 7 Research Group of Industrial Microbiology and Food Biotechnology (IMDO), Vrije Universiteit 22 Brussel, Brussels, Belgium 23 8 Laboratory of Microbiology, Department of Biochemistry and Microbiology, Ghent University, Ghent, 24 Belgium 25 9 Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, Canada 26 10 Department of Biological Sciences, University of Alberta, Edmonton, Canada 27 11 National Taiwan University, Dept.
    [Show full text]
  • Table S5. Components of the Probiotics in Each Included Clinical and Preclinical Literature
    Electronic Supplementary Material (ESI) for Food & Function. This journal is © The Royal Society of Chemistry 2021 Table S5. Components of the probiotics in each included clinical and preclinical literature. Study Type of strains Randomized controlled trials Ebrahim Kouchaki Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum and Lactobacillus (2017) fermentum Mahmoud Salami Bifidobacterium infantis, Bifidobacterium lactis, Lactobacillus reuteri, Lactobacillus casei, (2019) Lactobacillus plantarum and Lactobacillus fermentum Mehran Bacillus subtilis PXN 21, Bifidobacterium bifidum PXN 23, Bifidobacterium breve PXN 25, Rahimlou（2020） Bifidobacterium infantis PXN 27, Bifidobacterium longum PXN 30, Lactobacillus acidophilus PXN 35, Lactobacillus delbrueckii ssp. bulgaricus PXN 39, Lactobacillus casei PXN 37, Lactobacillus plantarum PXN 47, Lactobacillus rhamnosus PXN 54, Lactobacillus helveticus PXN 45, Lactobacillus salivarius PXN 57, Lactococcus lactis ssp. lactis PXN 63, Streptococcus thermophilus PXN 66 Preclinical studies Kobayashi et al Lactobacillus casei strain Shirota, Bifidobacterium breve strain Yakult (2009) Lavasani et al Lactobacillus paracasei, DSM 13434; Lactobacillus plantarum, DSM 15312 (HEAL9); (2010) Lactobacillus plantarum, DSM 15313 (HEAL19); Lactobacillus paracasei, PCC (Probi Culture Collection) 101 and Lactobacillus delbrueckii, subsp. bulgaricus, DSM 20081 Ochoa-Repáraz et al Bacteroides fragilis (2010) Takata et al Pediococcus acidilactici R037 (2011) Kobayashi et al Lactobacillus casei strain
    [Show full text]
  • Antimicrobial Activity of Lactococcus Lactis Subsp. Lactis Isolated
    microorganisms Article Antimicrobial Activity of Lactococcus lactis subsp. lactis Isolated from a Stranded Cuvier’s Beaked Whale (Ziphius cavirostris) against Gram-Positive and -Negative Bacteria Akihiko Suzuki and Miwa Suzuki * Laboratory of Aquatic Animal Physiology, Department of Marine Science and Resources, Graduate School of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa 252-0880, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-4668-43677 Abstract: In the present study, we isolated and characterized Lactococcus lactis (L. lactis) subsp. lactis from a female Cuvier’s beaked whale (Ziphius cavirostris) stranded in Shizuoka, Japan. Only five isolates (CBW1-5), grown on Lactobacilli de Man Rogosa Sharpe (MRS) agar plates prepared using 50% artificial seawater, were positive in L. lactis species-specific primer PCR. Their 16S rRNA sequences were highly similar to those of L. lactis subsp. lactis JCM 5805T. The Gram reaction, motility, gas production from glucose, catalase production, and growth conditions were consistent with those of the type strain. Additionally, carbohydrate utilization of the strains was consistent with previously reported marine organism-derived strains. The pH-neutralized cell-free culture supernatant of strain CBW2 inhibited the growth of Bacillus subtilis subsp. subtilis ATCC 6051 and Vibrio alginolyticus ATCC 17749, whereas protease treatment eliminated or diminished its inhibitory Citation: Suzuki, A.; Suzuki, M. activity. The strain possesses a precursor of the nisin structural gene (nisA), which showed 100% Antimicrobial Activity of Lactococcus homology with nisin Z, and nisin biosynthesis-related genes (nisB, nisC, nisT, nisP, nisF, nisI, and lactis subsp. lactis Isolated from a nisRK), suggesting that the strain produces a nisin-like substance.
    [Show full text]
  • A Taxonomic Note on the Genus Lactobacillus
    TAXONOMIC DESCRIPTION Zheng et al., Int. J. Syst. Evol. Microbiol. DOI 10.1099/ijsem.0.004107 A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae Jinshui Zheng1†, Stijn Wittouck2†, Elisa Salvetti3†, Charles M.A.P. Franz4, Hugh M.B. Harris5, Paola Mattarelli6, Paul W. O’Toole5, Bruno Pot7, Peter Vandamme8, Jens Walter9,10, Koichi Watanabe11,12, Sander Wuyts2, Giovanna E. Felis3,*,†, Michael G. Gänzle9,13,*,† and Sarah Lebeer2† Abstract The genus Lactobacillus comprises 261 species (at March 2020) that are extremely diverse at phenotypic, ecological and gen- otypic levels. This study evaluated the taxonomy of Lactobacillaceae and Leuconostocaceae on the basis of whole genome sequences. Parameters that were evaluated included core genome phylogeny, (conserved) pairwise average amino acid identity, clade- specific signature genes, physiological criteria and the ecology of the organisms. Based on this polyphasic approach, we propose reclassification of the genus Lactobacillus into 25 genera including the emended genus Lactobacillus, which includes host- adapted organisms that have been referred to as the Lactobacillus delbrueckii group, Paralactobacillus and 23 novel genera for which the names Holzapfelia, Amylolactobacillus, Bombilactobacillus, Companilactobacillus, Lapidilactobacillus, Agrilactobacil- lus, Schleiferilactobacillus, Loigolactobacilus, Lacticaseibacillus, Latilactobacillus, Dellaglioa,
    [Show full text]
  • Isolation and Identification of Lactic Acid Bacteria from Sourdough with High Exopolysaccharide Production Ability
    Food Sci. Biotechnol. Vol. 18, No. 2, pp. 384 ~ 389 (2009) ⓒ The Korean Society of Food Science and Technology Isolation and Identification of Lactic Acid Bacteria from Sourdough with High Exopolysaccharide Production Ability Seung Won Jung, Wang June Kim*, Kwang Geun Lee, Cheol Woo Kim1, and Wan Seob Noh Department of Food Science and Technology, Dongguk University, Seoul 100-715, Korea 1Korea Advanced Food Research Institute, Seoul 137-850, Korea Abstract To isolate lactic acid bacteria having high exopolysaccharides (EPS) production ability, 50 strains were initially isolated from the sourdough. Twenty-one strains formed highly mucoid colonies on the sucrose agar medium, which are indicative of active EPS synthesis. DU-07, DU-10, DU-12, DU-19, and DU-21 produced 11.51±0.167, 13.09±0.193, 12.72±0.108, 11.61±0.284, and 13.32±0.094 g/L EPS, respectively, in MRS medium. The isolated strains, DU-10, DU-12, and DU-21, were identified as Enterococcus flavescens, Enterococcus faecium, and Lactobacillus amylovorus, respectively, by using API 50CHL kit and determining partial sequences of their 16S rDNA. Especially, L. amylovorus DU-21 showed the highest production of EPS, as well as the highest inhibitory activities against pathogenic (p<0.05). Interestingly, the L. amylovorus DU-21 seem to be endemic to sourdough fermentations, as they have not been isolated from other environments. Keywords: exopolysaccharide, sourdough, lactic acid bacteria, screening, 16S rDNA gene Introduction should be 100:1 for optimal activities (10). Many inherent properties of sourdough rely on the metabolic activities of Polymers from plant, animal, and microbial origin play an its resident LAB: lactic fermentation, proteolysis, synthesis important role in food formulations.
    [Show full text]
  • Characterization of Commercial Probiotics: Antibiotic Resistance
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Dissertations, Theses, & Student Research in Food Food Science and Technology Department Science and Technology 8-2014 Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization Carmen Lucia Cano Roca University of Nebraska-Lincoln, [email protected] Follow this and additional works at: http://digitalcommons.unl.edu/foodscidiss Part of the Food Microbiology Commons Cano Roca, Carmen Lucia, "Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization" (2014). Dissertations, Theses, & Student Research in Food Science and Technology. 46. http://digitalcommons.unl.edu/foodscidiss/46 This Article is brought to you for free and open access by the Food Science and Technology Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Dissertations, Theses, & Student Research in Food Science and Technology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. i Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization by Carmen Lucia Cano Roca A THESIS Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Master of Science Major: Food Science and Technology Under the Supervision of Professor Jayne E. Stratton Lincoln, Nebraska August, 2014 ii Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization Carmen Lucia Cano Roca, M.S. University of Nebraska, 2014 Adviser: Jayne Stratton Probiotics, live microorganisms that beneficially affect the health of their host, must undergo extensive research to ensure they are safe for consumption and possess certain functional properties.
    [Show full text]
  • Probiotic G.I. 60'S
    Product Information Sheet – August 2015 Probiotic G.I. Introduced 2010 What Is It? derived from corn dextrose fermentation and palm oil. Pure Encapsulations® probiotic products contain a unique form of Probiotic G.I. is a shelf-stable probiotic blend designed to support gut rice starch produced through a natural enzymatic process. This associated lymphoid tissue composition and function, gastrointestinal proprietary starch has been extensively tested and is added to cell health and immune response in the G.I. tract. Each capsule provides protect the viability of the probiotic organisms. 10 billion CFU of the beneficial bacteria Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus casei, Bifidobacterium bifidum, Recommendations Bifidobacterium lactis and Streptococcus thermophilus.* Pure Encapsulations recommends 1–2 capsules daily, in divided Uses For Probiotic G.I. doses, with or between meals. Healthy Immune Response in the G.I. Tract: Probiotics are key players Are There Any Potential Side Effects Or in gastrointestinal health, promoting intestinal integrity and comfort. Precautions? Supplement use promotes colonization of the G.I. tract by competing for nutrients and attachment sites, and producing compounds which Probiotics may result in mild flatulence, which should subside limit the ability of certain microbes to adhere. Research indicates that with continued use. They may be contraindicated for use with the strains included in Probiotic G.I. provide particular support for a immunocompromised individuals. If pregnant or lactating, consult healthy immune response within the G.I. tract. Beneficial microflora your physician before taking this product. are crucial for proper gut associated lymphoid tissue (GALT) function Are There Any Potential Drug Interactions? and development.
    [Show full text]
  • 2017-Probiotics-And-Prebiotics.Pdf
    World Gastroenterology Organisation Global Guidelines Probiotics and prebiotics February 2017 WGO Review Team Francisco Guarner (Chair, Spain), Mary Ellen Sanders (Co-Chair, USA), Rami Eliakim (Israel), Richard Fedorak (Canada), Alfred Gangl (Austria), James Garisch (South Africa), Pedro Kaufmann (Uruguay), Tarkan Karakan (Turkey), Aamir G. Khan (Pakistan), Nayoung Kim (South Korea), Juan Andrés De Paula (Argentina), Balakrishnan Ramakrishna (India), Fergus Shanahan (Ireland), Hania Szajewska (Poland), Alan Thomson (Canada), Anton Le Mair (The Netherlands) Invited experts Dan Merenstein (USA) Seppo Salminen (Finland) WGO Global Guideline Probiotics and prebiotics 2 Contents 1 Probiotics and prebiotics—the concept ................................................................................ 4 1.1 History and definitions ....................................................................................................... 4 1.2 Prebiotics and synbiotics .................................................................................................... 5 1.3 Genera, species, and strains used as probiotics ................................................................. 6 1.4 Colonizing microbiota ......................................................................................................... 7 1.5 Mechanisms of action of probiotics ................................................................................... 8 2 Products, health claims, and commerce...............................................................................
    [Show full text]
  • Lactobacillus Bacteria in Breast Milk
    nutrients Review Lactobacillus Bacteria in Breast Milk Katarzyna Łubiech * and Magdalena Twaru˙zek Department of Physiology and Toxicology, Faculty of Biological Sciences, Kazimierz Wielki University, Chodkiewicza 30 St., 85-064 Bydgoszcz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-668339174 Received: 11 November 2020; Accepted: 8 December 2020; Published: 10 December 2020 Abstract: Breast milk is an optimal food for infants and toddlers. The composition of breast milk adapts to the needs of the developing organism, satisfying nutritional needs at an early stage of growth and development. The results of research to date have shown that breast milk is the best food for a child, containing not only nutrients but also biologically active substances that aid in the optimal, proper growth and development of infants. Among the many components of breast milk, an important element is the probiotic microflora, including bacteria of the genus Lactobacillus spp. These organisms exert a multidirectional, health-promoting effect on the body of children who consume breast milk. The number of lactic acid bacteria, including Lactobacillus, colonizing the breast milk environment and their species diversity varies and depends on many factors, both maternal and environmental. Breast milk, as a recommended food for infants, is an important source of probiotic microflora. The aim of this study was to present the current understanding of probiotic bacteria of the genus Lactobacillus present in breast milk. Keywords: breast milk; probiotic microflora; Lactobacillus spp.; infant nutrition; breastfeeding 1. Introduction Breast milk is a natural food for infants and young children. It satisfies the nutritional needs of a growing and developing infants on many levels.
    [Show full text]